Ferumoxytol-enhanced Imaging and Mapping in neuroAIDS

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions
AIDS Dementia Complex
Interventions
DRUG

Ferumoxytol

All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion

Trial Locations (1)

96813

Hawaii Center for AIDS, Honolulu

All Listed Sponsors
collaborator

Hawaii Pacific Health

OTHER

collaborator

University of Hawaii

OTHER

collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Beau Nakamoto

OTHER

NCT02678767 - Ferumoxytol-enhanced Imaging and Mapping in neuroAIDS | Biotech Hunter | Biotech Hunter